Effect of neuroleptics on cytochrome P450 2C11 (CYP2C11) in rat liver

Pharmacological Reports

Volumn 63, Issue 6, 2011, Pages 1491-1499

  Haduch, Anna ^a   Wójcikowski, Jacek ^a   Daniel, Władysława A ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Chronic treatment; CYP2C11; Direct effect; Neuroleptics; One day treatment; Rat

Indexed keywords

CHLORPROMAZINE; CYTOCHROME P450 2C11; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; PERAZINE; PROMAZINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HYDROXYLATION; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT;

EID: 84857467171     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70713-7     Document Type: Article

References (54)

1. Agrawal AK, Shapiro BH: Differential expression of gender-dependent hepatic isoforms of cytochrome P-450 by pulse signals in the circulating masculine episodic growth hormone profile of the rat. J Pharmacol Exp Ther, 2000, 292, 228-237. (Pubitemid 30026375)
2. Azarpira N, Namazi S, Hendijani F, Banan M, Darai M: Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran. Pharmacol Rep, 2010, 62, 740-746.
3. Badger TM, Ronis MJJ, Lumpkin CK, Valentine CR, Shahare M, Irby D, Huang J, Mercado C et al.: Effects of chronic ethanol on growth hormone secretion and hepatic cytochrome P450 isoenzymes of the rat. J Pharmacol Exp Ther, 1993, 264, 438-447. (Pubitemid 23309234)
4. Barbosa-Sicard, E, Markovic M, Honeck H, Christ B, Muller DN, Schunck WH: Eicosapentaenoic acid metabolism by cytochrome P450 enzymes of the CYP2C subfamily. Biochem Biophys Res Commun, 2005, 329, 1275-1281. (Pubitemid 40568707)
5. Belic A, Temesvári M, Kohalmy K, Vrzal R, Dvorak Z, Rozman D, Monostory K: Investigation of the CYP2C9 induction profile in human hepatocytes by combining experimental and modelling approaches. Curr Drug Metab, 2009, 10, 1066-1074.
6. Chen G-F, Ronis MJ, Thomas PE, Flint DJ, Badger TM: Hormonal regulation of microsomal cytochrome P450 2C11 in rat liver and kidney. J Pharmacol Exp Ther, 1997, 283, 1486-1494. (Pubitemid 28016525)
7. Choi HK, Waxman DJ: Plasma growth hormone pulse activation of hepatic JAK-STAT5 signaling: developmental regulation and role in male-specific liver gene expression. Endocrinology, 2000, 141, 3245-3255. (Pubitemid 32269012)
8. Creese I, Burt DR, Snyder SH: Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science, 192, 481-483.
9. Daniel WA: The influence of long-term treatment with psychotropic drugs on cytochrome P450: the involvement of different mechanisms. Expert Opin Drug Metab Toxicol, 2005, 1, 203-217.
10. Daniel WA, Haduch A, Wójcikowski J: Inhibition of rat liver CYP2D in vitro and after 1-day and long-term exposure to neuroleptics in vivo - possible involvement ofdifferent mechanisms. Eur Neuropsychopharmacol, 2005, 15, 103-110. (Pubitemid 39574405)
11. Daniel WA, Syrek M, Haduch A, Wójcikowski J: Pharmacokinetics and metabolism of thioridazine during coadministration of tricyclic antidepressants. Br J Pharmacol, 2000, 131, 287-295.
12. Daniel WA, Syrek M, Wójcikowski J: The influence of selective serotonin reuptake inhibitors on the plasma and brain pharmacokinetics of the simplest phenothiazine neuroleptic promazine in the rat. Eur Neuropsychopharmacol, 1999, 9, 337-344. (Pubitemid 29253786)
13. Daniel WA, Wójcikowski J: Contribution of lysosomal trapping to the total tissue uptake of psychotropic drugs. Pharmacol Toxicol, 1997, 80, 62-68. (Pubitemid 27078228)
14. De Mol NJ, Becht ABC, Koenen J, Lodder G: Irreversible binding with biological macromolecules and effect of bacterial mutagenity tests on the radical cation of promethazine and photoactivated promethazine. Comparison with chlorpromazine. Chem Biol Interact, 1986, 57, 73-83. (Pubitemid 16163813)
15. Haduch A, Ogórka T, Boksa J, Daniel WA: Interactions between neuroleptics and CYP2C6 in rat liver - in vitro and ex vivo study. Pharmacol Rep, 2005, 57, 872-877.
16. Haduch A, Wójcikowski J, Daniel WA: Direct effects of neuroleptics on the activity of CYP2A in the liver of rats. Pharmacol Rep, 2005, 57, 867-871.
17. Haduch A, Wójcikowski J, Daniel WA: The activity of cytochrome P450 CYP2B in rat liver during neuroleptic treatment. Pharmacol Rep, 2007, 59, 606-612.
18. Hanagama M, Inoue H, Kamiya M, Shinone K, Nata M: Gene expression on liver toxicity induced by administration of haloperidol in rats with severe fatty liver. Leg Med, 2008, 10, 177-184.
19. Iber H, Chen Q, Sewer M, Morgan ET: Regulation of hepatic cytochrome P450 2C11 by glucocorticoids. Arch Biochem Biophys, 1997, 343, 305-310. (Pubitemid 27400624)
20. Kelder PP, Fischer MJE, De Mol NJ, Janssen LHM: Oxidation of chlorpromazine by methemoglobin in the presence of hydrogen peroxide. Formation of chlorpromazine radical cation and its covalent binding to methemoglobin. Arch Biochem Biophys, 1991, 284, 313-319.
21. Kobayashi K, Urashima K, Shimada N, Chiba K: Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems oft he rat. Biochem Pharmacol, 2002, 63, 889-896. (Pubitemid 34243002)
22. Legraverend C, Mode A, Westin S, Strom A, Eguchi H, Zaphiropoulos PG, Gustafsson JA: Transcriptional regulation of rat P-450 2C gene subfamily members by the sexually dimorphic pattern of growth hormone secretion. Mol Endocrinol, 1992, 6, 259-266.
23. Levine M, Law EYW, Bandiera SM, Chang TKH, Bellward GD: In vivo cimetidine inhibits hepatic CYP2C6 and CYP2C11 but not CYP1A1 in adult male rats. J Pharmacol Exp Ther, 1998, 284, 493-499. (Pubitemid 28086633)
24. Lewis DFV: Substrate selectivity and metabolism. In: Cytochromes P450. Structures and function. Taylor & Francis, London and New York, 2001, 76-117.
25. Masubuchi Y, Ose A, Horie T: Mechanism-based inactivation of CYP2C11 by diclofenac. Drug Metab Dispos, 2001, 29, 1190-1195. (Pubitemid 32800229)
26. Monostory K, Dvorak Z: Steroid regulation of drugmetabolizing cytochrome P450. Curr Drug Metab, 2011, 12, 154-172.
27. Morgan ET, MacGeogh C, Gustafsson J-A: Hormonal and developmental regulation of the expression of the hepatic microsomal steroid 16α-hydroxylase cytochrome P-450 apoprotein in the rat. J Biol Chem, 1985, 260, 11895-11898. (Pubitemid 16228343)
28. Murray M: Inhibition and induction of cytochrome P450 2B1 in rat liver by promazine and chlorpromazine. Biochem Pharmacol, 1992, 44, 1219-1222.
29. Nedelcheva V, Gut I: P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer. Xenobiotica, 1994, 24, 1151-1175.
30. Pampori NA, Agrawal AK, Shapiro BH: Infusion of gender-dependent plasma growth hormone profiles into intact rats: effects of subcutaneous, intraperitoneal, and intravenous routes of rat and human growth hormone on endogenous circulating growth hormone profiles and expression of sexually dimorphic hepatic CYP isoforms. Drug Metab Dispos, 2001, 29, 8-16. (Pubitemid 32042156)
31. Pascussi JM, Gerbal Chaloin S, Duret C, Daujat- Chavanieu M, Vilarem MJ, Maurel P: The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences. Annu Rev Pharmacol Toxicol, 2008, 48, 1-32. (Pubitemid 351738147)
32. Rahmaniyan M, Patrick K, Bell NH: Characterization of recombinant CYP2C11: a vitamin D 25-hydroxylase and 24-hydroxylase. Am J Physiol Endocrinol Metab, 2005, 288, 753-760.
33. Rane A, Liu Z, Levol R, Bjelfman C, Thyr C, Ericson H, Hansson T et al.: Differential effects of neuroleptic agents on hepatic cytochrome P-450 isoenzymes in the male rat. Biochim Biophys Acta, 1996, 1291, 60-66. (Pubitemid 26284326)
34. Rendic S, Di Carlo FJ: Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab Rev, 1997, 29, 413-580. (Pubitemid 27293618)
35. Richelson E, Nelson A: Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol, 1984, 103, 197-204. (Pubitemid 14028974)
36. Roman RJ: P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev, 2002, 82, 131-185.
37. Ryan DE, Levin W: Purification and characterization of hepatic microsomal cytochrome P-450. Pharmacol Ther, 1990, 45, 153-239. (Pubitemid 20008907)
38. Sonderfan AJ, Arlotto MP, Dutton DR. McMillen SK, Parkonson A: Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch Biochem Biophys, 1987, 255, 27-41.
39. Souèek P, Gut I: Cytochromes P-450 in rats: structures, functions, properties and relevant human forms. Xenobiotica, 1992, 22, 83-103.
40. Sundseth SS, Alberta JA, Waxman DJ: Sex-specific, growth hormone-regulated transcription of the cytochrome P450 2C11 and 2C12 genes. J Biol Chem, 1992, 267, 3907-3914.
41. Tateishi T, Kumai T, Watanabe M, Tanaka M, Kobayashi S: A comparison of the effect of five phenothiazines on hepatic CYP isoenzymes in rats. Pharmacol. Toxicol, 1999, 85, 252-256.
42. Tinel M, Elkahwaji J, Robin MA, Fardel N, Descatoire V, Haouzi D, Berson A, Pessayre D: Interleukin-2 overexpresses c-myc and down-regulates cytochrome P-450 in rat hepatocytes. J Pharmacol Exp Ther, 1999, 289, 649-655. (Pubitemid 29191214)
43. Večeřa R, ZachařováA, Orolin J, Strojil J, Škottová N, Anzenbacher P: Fenofibrate-induced decrease of expression of CYP2C11 and CYP2C6 in rat. Biopharm Drug Dispos, 2011, 32, 482-487.
44. Waxman DJ: Interactins of hepatic cytochromes P450 with steroid hormones. Biochem Pharmacol, 1988, 37, 71-84.
45. Waxman DJ, Holloway MG: Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol, 2009, 76, 215-228.
46. Waxman DJ, O'Connor C: Growth hormone regulation of sex-dependent liver gene expression. Mol Endocrinol, 2006, 20, 2613-2629. (Pubitemid 44833525)
47. Wong SL, Cao G, Mack RJ, Granneman GR: Pharmacokinetics of sertrindole in healthy young and elderly male and female subjects. Clin Pharmacol Ther, 1997, 62, 157-164. (Pubitemid 27373463)
48. Wójcikowski J, Daniel WA: Distribution interactions between perazine and antidepressant drugs. In vivo studies. Pol J Pharmacol, 2000, 52, 449-457. (Pubitemid 32045908)
49. Wójcikowski J, Daniel WA: Identification of factors mediating the effects of the brain dopaminergic system on the expression of cytochrome P450 in the liver. Pharmacol Rep, 2008, 60, 966-971.
50. Wójcikowski J, Daniel WA: The brain dopaminergic system as an important center regulating liver cytochrome P450 in the rat. Expert Opin Drug Metab Toxicol, 2009, 5, 631-645.
51. Wójcikowski J, Daniel WA: The role of the nervous system in the regulation of liver cytochrome P450. Curr Drug Metab, 2011, 12, 124-138.
52. Wójcikowski J, Daniel WA: Thioridazine-fluoxetine interaction at the level of the distribution process in vivo. Pol J Pharmacol, 2002, 54, 647-654. (Pubitemid 36124515)
53. Wójcikowski J, Gołembiowska K, Daniel WA: Regulation of liver cytochrome P450 by activation of brain dopaminergic system: physiological and pharmacological implications. Biochem Pharmacol, 2008, 76, 258-267.
54. Wójcikowski J, Gołembiowska K, Daniel WA: The regulation of liver cytochrome P450 by the brain dopaminergic system. Curr Drug Metab, 2007, 8, 631-638. (Pubitemid 47209100)